CalciMedica (NASDAQ: CALC) appoints Dr. Evgeny Zaytsev to board
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
CalciMedica, Inc. reported changes to its board of directors. On July 2, 2026, the board expanded from seven to eight members and appointed Evgeny Zaytsev, M.D., Ph.D. as a Class I director, with a term running until the 2027 annual meeting of stockholders.
Under the company’s non-employee director compensation policy, he will receive a pro-rated annual cash retainer of $40,000 and an option to purchase 20,000 shares of common stock, vesting monthly over three years from July 2, 2026, subject to continuous service. CalciMedica also disclosed that director Fred Middleton intends to retire effective at the 2026 annual meeting, at which time the board size will return to seven, and that his retirement does not stem from any disagreement with the company.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Board size after expansion: 8 directors
Board size after retirement: 7 directors
Annual cash retainer: $40,000
+3 more
6 metrics
Board size after expansion
8 directors
Increased from seven on July 2, 2026
Board size after retirement
7 directors
To be reduced upon 2026 annual meeting
Annual cash retainer
$40,000
Non-employee director cash retainer, pro-rated
Stock option grant
20,000 shares
Option granted to Dr. Zaytsev, vests over three years
Appointment effective date
July 2, 2026
Effective date of Dr. Zaytsev’s board appointment
Term end for new director
2027 annual meeting
Expiration of Dr. Zaytsev’s Class I director term
Key Terms
Class I director, Nominating and Corporate Governance Committee, Compensation Policy, Indemnity Agreement, +1 more
5 terms
Class I director financial
"appointed Evgeny Zaytsev, M.D., Ph.D., as a Class I director of the Company"
A class I director is a member of a company’s board who belongs to one of several groups whose terms expire in a specified year under a staggered election system; each class is elected on a different cycle so only a portion of the board faces re-election each year. This matters to investors because it affects how quickly control of the board can change, the company’s continuity and oversight, and the ease of mounting or defending against takeover efforts—think of a team where only some players are replaced each season rather than the whole roster at once.
Nominating and Corporate Governance Committee financial
"upon recommendation of the Nominating and Corporate Governance Committee of the Board"
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
Compensation Policy financial
"Pursuant to the Company’s compensation policy for non-employee directors (the “Compensation Policy”)"
Indemnity Agreement financial
"will enter into the Company’s standard form of Indemnity Agreement for directors of the Company"
Item 404(a) of Regulation S-K regulatory
"no transactions in which Dr. Zaytsev has an interest that would require disclosure under Item 404(a) of Regulation S-K"
FAQ
What did CalciMedica (CALC) announce in this July 2026 Form 8-K?
CalciMedica announced a board expansion and director changes. The board increased from seven to eight members, appointed Dr. Evgeny Zaytsev as a Class I director, and disclosed that long-serving director Fred Middleton will retire at the 2026 annual meeting of stockholders.
Who is Evgeny Zaytsev and what is his role at CalciMedica (CALC)?
Evgeny Zaytsev, M.D., Ph.D., has been appointed a Class I director. He joins CalciMedica’s board effective July 2, 2026, with his term expiring at the 2027 annual meeting of stockholders. The company states there are no related-party transactions requiring disclosure.
What compensation will Dr. Zaytsev receive as a CalciMedica (CALC) director?
Dr. Zaytsev will receive an annual cash retainer of $40,000, pro-rated based on days served. He was also granted an option to purchase 20,000 CalciMedica common shares, vesting monthly over three years from July 2, 2026, subject to his continuous board service.
How many CalciMedica (CALC) stock options were granted to Dr. Zaytsev?
CalciMedica granted Dr. Zaytsev an option to purchase 20,000 shares of its common stock. The option vests in monthly installments over a three-year period starting July 2, 2026, conditioned on his continued service as a non-employee director on the board.
When will CalciMedica (CALC) director Fred Middleton retire from the board?
Fred Middleton informed the board he will retire effective at CalciMedica’s 2026 annual meeting of stockholders. After his retirement, the board size will be reduced from eight back to seven directors, and the company states his retirement is not due to any disagreement.